SCYNEXIS Inc (SCYX)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
$3.84-2.54%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-11-04
QuarterlyIQ Insights · SCYX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -62.1% |
| Our one-year growth estimate | diamond | -93.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 31.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 2 industry peers · Company calendar date is not available
SCYX — litigation filed
Dated 2026-09-28
Regulation FD Disclosure. On September 28, 2026, the Company issued a press release announcing the BARDA Contract. A copy of the press release is filed herewith as Exhibit 99.1 and is incorporated herein by reference. The information furnished under this Item 7.01 (including Exhibit 99.1), shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securiti…
Why it matters: The company said its cash runway extends into 2029. Any shorter runway would raise pressure on its plans for both programs.
Worry ifThe November 4 update puts the cash runway before 2029 or reports a need for more funding.
Less concerning ifThe company reaffirms a cash runway into 2029 and reports no new financing need.
Why it matters: The contract could provide up to $214 million, but that amount depends on BARDA exercising options. Option awards would fund later development steps.
Supportive ifBARDA uses one or more contract options. This adds funds beyond the initial $18.5 million base period.
Worry ifBARDA does not use more options, or the company says the contract ends after the base period.
Why it matters: SCY-770 is the lead ADPKD program. Clear Phase 2 plans would show progress toward testing it in patients.
Supportive ifThe company gives a Phase 2 start window and trial details, with no delay to its prior milestones.
Worry ifThe company delays the Phase 2 start or reports a change to its prior development milestones.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$257 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $653 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,545 loss on $10,000 · 35.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.